{"id":"clofarabine-fludarabine-and-busulfan-cloflubu","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Clofarabine and fludarabine are purine nucleoside analogs that inhibit ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells. Busulfan is an alkylating agent that cross-links DNA. Together, this triple-agent combination provides intensive myeloablation to eliminate malignant and host bone marrow cells before stem cell transplantation.","oneSentence":"CloFluBu is a combination chemotherapy regimen that inhibits DNA synthesis and repair through three nucleoside analogs, used as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:23.100Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen for hematopoietic stem cell transplantation in acute leukemias and lymphomas"}]},"trialDetails":[{"nctId":"NCT05477589","phase":"PHASE3","title":"Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2022-06-07","conditions":"Acute Myeloid Leukemia (AML) in Remission, Stem Cell Transplantation","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CloFluBu"],"phase":"phase_3","status":"active","brandName":"clofarabine, fludarabine and busulfan, CloFluBu","genericName":"clofarabine, fludarabine and busulfan, CloFluBu","companyName":"Vastra Gotaland Region","companyId":"vastra-gotaland-region","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CloFluBu is a combination chemotherapy regimen that inhibits DNA synthesis and repair through three nucleoside analogs, used as a myeloablative conditioning regimen prior to hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in acute leukemias and lymphomas.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}